DSC Equity Fund – Healthcare A|A

Reference Data

ISIN AT0000A1FNT0
Valor Number 28871817
Bloomberg Global ID
Fund Name DSC Equity Fund – Healthcare A|A
Fund Provider Dreyfus Söhne & Cie AG, Banquiers Aeschenvorstadt 16 | Postfach
4051 Basel
Schweiz
Phone: +41 61 286 66 66
Web: https://www.dreyfusbank.ch
Fund Provider Dreyfus Söhne & Cie AG, Banquiers
Representative in Switzerland Dreyfus Söhne & Cie AG, Banquiers
Basel
Distributor(s) Dreyfus Söhne & Cie AG, Banquiers
Basel
Asset Class Equities
EFC Category
Distribution Policy Distribution
Home Country Austria
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** N/A
Peculiarities

Fund Prices

Current Price * 218.08 CHF 20.01.2026
Previous Price * 220.36 CHF 19.01.2026
52 Week High * 237.48 CHF 04.03.2025
52 Week Low * 186.68 CHF 08.08.2025
NAV * 218.08 CHF 20.01.2026
Issue Price * 224.63 CHF 20.01.2026
Redemption Price * 218.08 CHF 20.01.2026
Closing Price *
Indicative Minimum Price
Fund Assets *** 39,976,181
Unit/Share Assets *** 38,267,628
Trading Information SIX

Performance

YTD Performance +1.62% 30.12.2025
20.01.2026
1 month +1.97% 22.12.2025
20.01.2026
3 months +8.25% 20.10.2025
20.01.2026
6 months +15.34% 21.07.2025
20.01.2026
1 year -3.98% 20.01.2025
20.01.2026
2 years -1.62% 22.01.2024
20.01.2026
3 years -3.16% 20.01.2023
20.01.2026
5 years -1.29% 20.01.2021
20.01.2026

Tax Data

Equity Participation Rate in % 95.78
Share of Total Fund Assets in %
Real Estate Rate in % 0.00
ADDI
ADDI Date

Top 10 Holdings ***

iShares MSCI Wld HlthCrSect AdvcdETF$Inc 8.07%
Eli Lilly and Co 7.88%
Johnson & Johnson 6.97%
AstraZeneca PLC 4.40%
AbbVie Inc 3.98%
Merck & Co Inc 3.77%
Abbott Laboratories 3.63%
UnitedHealth Group Inc 3.51%
Roche Holding AG 3.36%
Thermo Fisher Scientific Inc 3.35%
Last data update 31.12.2025

Cost / Risk

TER 1.52%
TER date 31.10.2025
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.49%
SRRI ***
SRRI date *** 31.12.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)